Registration Dossier

Toxicological information

Acute Toxicity: oral

Currently viewing:

Administrative data

Endpoint:
acute toxicity: oral
Type of information:
experimental study
Adequacy of study:
key study
Study period:
from 2012-06-08 to 2012-12-04
Reliability:
1 (reliable without restriction)
Rationale for reliability incl. deficiencies:
other: Study conducted in compliance with international standard guidelines under GLP conditions. The study report was well documented with all mandatory information included.

Data source

Reference
Reference Type:
study report
Title:
Unnamed
Year:
2012
Report Date:
2012

Materials and methods

Test guidelineopen allclose all
Qualifier:
according to
Guideline:
OECD Guideline 423 (Acute Oral toxicity - Acute Toxic Class Method)
Deviations:
no
Qualifier:
according to
Guideline:
EU Method B.1 tris (Acute Oral Toxicity - Acute Toxic Class Method)
Deviations:
no
Qualifier:
according to
Guideline:
EPA OPPTS 870.1100 (Acute Oral Toxicity)
Deviations:
no
Qualifier:
according to
Guideline:
other: 12 NohSan N° 8147, JMAFF, 2002
Deviations:
no
GLP compliance:
yes (incl. certificate)
Remarks:
2012-07-09
Test type:
acute toxic class method
Limit test:
no

Test material

Reference
Name:
Unnamed
Type:
Constituent
Test material form:
other: liquid
Details on test material:
- Name of test material (as cited in study report): Phosphoric acid, mono and bis(branched and linear pentyl) ester

Test animals

Species:
rat
Strain:
Wistar
Sex:
female
Details on test animals and environmental conditions:
TEST ANIMALS
- Source: Harlan Laboratories UK Ltd., Oxon, UK
- Age at study initiation: eight to twelve weeks
- Weight at study initiation: The bodyweights fell within an interval of ±20% of the mean initial bodyweight of the first treated group (from 151g to 171 g)
- Fasting period before study: Yes
- Housing: in groups of three in suspended solid-floor polypropylene cages furnished with woodflakes
- Diet (e.g. ad libitum): 2014C Teklad Global Rodent diet supplied by Harlan Laboratories UK Ltd., Oxon, UK
- Water (e.g. ad libitum): free access to mains drinking
- Acclimation period: at least five days

ENVIRONMENTAL CONDITIONS
- Temperature (°C): 19 to 25°C
- Humidity (%): 30 to 70%
- Air changes (per hr): fifteen changes per hour
- Photoperiod (hrs dark / hrs light): the lighting was controlled by a time switch to give twelve hours continuous light (06:00 to 18:00) and twelve hours darkness

IN-LIFE DATES: From: 04 September 2012 To: 11 October 2012

Administration / exposure

Route of administration:
oral: gavage
Vehicle:
other: DMSO for 300 mg/kg bw and no vehicle for 2000 mg/kg bw
Details on oral exposure:
VEHICLE
For the 300 mg/kg bw dose level:
- Concentration in vehicle: 30 mg/mL
- Amount of vehicle (if gavage): 10 mL/kg bw
- Justification for choice of vehicle: Dimethyl sulphoxide was used because the test item did not dissolve in distilled water or arachis oil
- Lot/batch no. (if required): No data
- Purity: No data

For the 2000 mg/kg dose level: the test item was used as supplied. The specific gravity was determined and used to calculate the appropriate dose volume for the required dose level.The specific gravity used for the calculation was 1.082.

MAXIMUM DOSE VOLUME APPLIED: 10 mL/kg bw

CLASS METHOD (if applicable)
- Rationale for the selection of the starting dose: Based on results with similar susbtances
Doses:
300 mg/kg bw
2000 mg/kg bw
No. of animals per sex per dose:
3 females at 300 mg/kg bw
6 females at 2000 mg/kg bw
Control animals:
no
Details on study design:
- Duration of observation period following administration: 14 days
- Frequency of observations and weighing:
+ Observations: The first day: 0.5h, 1h, 2h, 4h and then once daily
+ Weighing: day 0, 7 and 14

- Necropsy of survivors performed: yes
- Other examinations performed: clinical signs, body weight
Statistics:
No statistics were performed

Results and discussion

Preliminary study:
not applicable
Effect levels
Sex:
female
Dose descriptor:
LD50
Effect level:
> 2 000 - < 5 000 mg/kg bw
Based on:
test mat.
Mortality:
One animal treated at a dose level of 2000 mg/kg bw was killed for humane reasons, two days after dosing, due to the occurrence of clinical signs of toxicity that exceeded the moderate severity limit set forth in the UK Home Office Project Licence. There were no deaths at a dose level of 300 mg/kg bw.
Clinical signs:
Hunched posture and ataxia were noted in both dose groups. Additional signs of systemic toxicity noted in animals treated at a dose level of 2000 mg/kg were decreased respiratory rate, gasping, noisy or laboured respiration, pilo-erection, tiptoe gait, pallor of the extremities, lethargy, diuresis, increased salivation and red/brown staining around the eyes, mouth and snout.
See Tables 7.2.1/2 and 3
Body weight:
One animal treated at a dose level of 2000 mg/kg bw showed bodyweight loss during the first and second week of the study. One animal treated at a dose level of 2000 mg/kg bw showed expected gain in bodyweight during the first week but bodyweight loss during the second week. Remaining surviving animals showed expected gains in bodyweight over the study period.

See Tables 7.2.1/4 and 5
Gross pathology:
Abnormalities noted at necropsy of the animal that was humanely killed during the study were haemorrhagic lungs, dark kidneys and epithelial sloughing of the gastric mucosa and non-glandular epithelium of the stomach. No abnormalities were noted at necropsy of animals that were killed at the end of the study.
See Tables 7.2.1/ 6 and 7
Other findings:
No data

Any other information on results incl. tables

Table 7.2.1/2: Individual Clinical Obsevations- 300 mg/kg bw

Dose

Level

mg/kg bw

Animal

Number

and Sex

Effects Noted After Dosing

(Hours)

Effects Noted During Period After Dosing

(Days)

½

1

2

4

1

2

3

4

5

6

7

8

9

10

11

12

13

14

300

1-0

Female

HA

HA

HA

HA

H

0

0

0

0

0

0

0

Ä

0

0

0

0

0

1-1

Female

HA

HA

HA

HA

0

0

0

0

0

0

0

0

Ä

0

0

0

0

0

1-2

Female

HA

HA

HA

HA

0

0

0

0

0

0

0

0

Ä

0

0

0

0

0

 

0 = No signs of systemic toxicity

H = Hunched posture

A = Ataxia

Ä= Due to a technician error observation not performed


Table 7.2.1/3: Individual Clinical Obsevations- 2000 mg/kg bw

 

Dose

Level

mg/kg bw

Animal

Number

and Sex

Effects Noted After Dosing

(Hours)

Effects Noted During Period After Dosing

(Days)

½

1

2

4

1

2

3

4

5

6

7

8

9

10

11

12

13

14

2000

 

2-0

Female

H

H

H

(HPSDu

SsLWt)

H

H

HPWt

HPWtE

HPWtE

HEWt

0

0

0

0

0

0

0

0

0

2-1

Female

H

H

H

(H)

H

H

H

HP

HP

H

0

0

0

0

0

0

0

0

0

2-2

Female

H

H

H

(HSSm

RlWt)

H

H

HLRdRgRlRn

SeSmSsX*

0

0

0

0

0

0

0

0

0

0

0

0

3-0

Female

HA

HA

H

H

0

0

0

0

0

0

0

0

0

0

0

0

0

0

3-1

Female

H

H

H

H

Rn

Rn

0

0

0

0

0

0

0

0

0

0

0

0

3-2

Female

H

H

H

H

0

0

0

0

0

0

0

0

0

0

0

0

0

0

 

0 = No signs of systemic toxicity Rd = Decreased respiratory rate Rg = Gasping respiration Rn = Noisy respiration

Rl = Laboured respiration P = Pilo-erection Wt = Tiptoe gait A = Ataxia

E = Pallor of the extremities L = Lethargy Du = Diuresis S = Increased salivation

Se = Red/brown staining around the eyes Sm = Red/brown staining around the mouth Ss = Red/brown staining around the snout

( ) = Observation noted approximately 3 hours after dosing H = Hunched posture

X*= Animal killed for humane reasons due to the occurrence of clinical signs of toxicity that exceeded the moderate severity limit set forth in the UK HomeOffice Project Licence


Table 7.2.1/4: Individual Bodyweights and Weekly Bodyweight Changes - 300 mg/kg bw

Dose Level

mg/kg bw

Animal Number

and Sex

Bodyweight (g) at Day

Bodyweight Gain (g) During Week

0

7

14

1

2

300

1-0

Female

165

192

208

27

16

1-1

Female

171

201

214

30

13

1-2

Female

162

189

201

27

12

Table 7.2.1/5 Individual Bodyweights and Weekly Bodyweight Changes - 2000 mg/kg bw

Dose Level

mg/kg bw

Animal Number

and Sex

Bodyweight (g) at Day

Bodyweight (g)

at Death

Bodyweight Gain (g) During Week

0

7

14

1

2

2000

2-0

Female

151

143

123

 

-8

-20

2-1

Female

169

172

185

 

3

13

2-2

Female

162

-

-

156

-

-

3-0

Female

163

173

191

 

10

18

3-1

Female

159

170

177

 

11

7

3-2

Female

147

160

134

 

13

-26

- = Animal dead


Table 7.2.1/6 Individual Necropsy Findings - 300 mg/kg bw

Dose Level

mg/kg bw

Animal Number and Sex

Time of Death

Macroscopic Observations

300

1-0

Female

Killed Day 14

No abnormalities detected

1-1

Female

Killed Day 14

No abnormalities detected

1-2

Female

Killed Day 14

No abnormalities detected

Table 7.2.1/7 Individual Necropsy Findings - 2000 mg/kg bw

Dose Level

mg/kg bw

Animal Number and Sex

Time of Death

Macroscopic Observations

2000

2-0

Female

Killed Day 14

No abnormalities detected

2-1

Female

Killed Day 14

No abnormalities detected

2-2

Female

Humanely killed Day 2

Lungs: haemorrhagic

Kidneys: dark

Gastric mucosa: epithelial sloughing

Non-glandular epithelium of the stomach: epithelial sloughing

3-0

Female

Killed Day 14

No abnormalities detected

3-1

Female

Killed Day 14

No abnormalities detected

3-2

Female

Killed Day 14

No abnormalities detected

Applicant's summary and conclusion

Interpretation of results:
not classified
Remarks:
Migrated information Criteria used for interpretation of results: EU
Conclusions:
The acute oral median lethal dose (LD50) of the test item in the female Wistar strain rat was estimated to be greater than 2000 mg/kg bodyweight.
Executive summary:

In an acute oral toxicity study, performed according to acute toxicity class method Procedure (OECD Guideline 423; EC test method B1.tris, EPA OPPTS870.1100 and Japanese MAFF, 2000) and in compliance with the GLP, groups of female Wistar rats were given a single oral dose of Phosphoric acid, mono- and bis(branched and linear pentyl) esters by gavage at the dose of 300 or 2000 mg/kg bw. The test item was administered as supplied for the dose of 2000 mg/kg bw and diluted in DMSO for the lowest dose of 300 mg/kg bw. Clinical signs, mortality and body weight gain were checked for a period of up to 14 days. All surviving animals were sacrificed at the end of the study and necropsied for gross abnormalities.

 

The starting dose was stated as 300 mg/kg bw and tested in a group of 3 female rats. As no mortality occurred and no severe clinical signs were observed,two groups of 3 female rats further fasted were given a single oral dose of 2000 mg/kg bw. At this dose, one animal was killed for ethical reasons 2 days after dosing, due to the occurrence of clinical signs of toxicity that exceeded the moderate severity limit set in the UK Home Office Project Licence. Hunched posture and ataxia was noted in both dose groups (300 and 2000 mg/kg bw). Additional signs of systemic toxicity noted in animals treated at a dose level of 2000 mg/kg bw were decrease respiratory rate, gasping, noisy or labored respiration, pilo-erection, tiptoe gait, pallor of the extremities, lethargy, diuresis, increased salivation and red/brown staining around the eyes and snout. No clinicals signs were observed from Day 7 up to the end of the observation period. Furthermore, two animals exposed to the dose of 2000 mg/kg bw showed body weight loss during the study. No abnormalities were detected at the necropsy at the end of the study. The rat killed on day 2 showed haemorrhagic lung, dark kidneys, epithelial sloughing in gastric mucosa and in non glandular epithelium of the stomach.

Under these experimental conditions, the Ld50 in rat was determined to be higher than 2000 mg/kg bw. Therefore no classification for acute oral toxicity is required for Phosphoric acid, mono- and bis(branched and linear pentyl) esters neither according to the criteria of the Regulation (EC) 1272/2008 (CLP including ATP3) nor according to the criteria of the Directive 67/548/EEC.

This study is considered as acceptable and satisfies the requirement for acute oral toxicity endpoint.